| Todd Garland |
Todd Garland is Chief Commercial Officer of NanoString Technologies, Inc.
He previously occupied the position of Vice President & General Manager at BD Biosciences Clontech and Chief Commercial Officer at Cytek Biosciences, Inc.
Mr. Garland received an undergraduate degree from California Polytechnic State University (San Luis Obispo) and an MBA from the University of Michigan. |
| Mark A. Winham |
Currently, Mark A. Winham is Senior Vice President-Operations for NanoString Technologies, Inc.
In his past career Mr. Winham held the position of Chief Operating Officer at Millennium Health LLC, Chief Operating Officer for Human Longevity, Inc., Chief Scientific & Operating Officer at Genomic Life, Inc., Principal at Johnson & Johnson, Principal at Sanofi-Aventis U.S. LLC, Vice President-Global Manufacturing at Life Technologies Corp. and Principal at National Health Service.
Mark A. Winham received an undergraduate degree from Napier University. |
| Joseph M. Beechem |
Presently, Joseph M. Beechem holds the position of Chief Scientific Officer, SVP-R&D at NanoString Technologies, Inc.
In the past he held the position of Chief Scientific Officer for Invitrogen Corp., Chief Technology Officer at Life Technologies Corp., Biosciences Director at Molecular Probes, Inc. and Associate Professor at Vanderbilt University.
He received an undergraduate degree from Northern Kentucky University and a doctorate from The Johns Hopkins University. |
| Tom Bailey |
Presently, Tom Bailey holds the position of Chief Financial Officer of NanoString Technologies, Inc. and Operating Partner at Shore Capital Partners LLC. He is also on the board of IZI Medical Products LLC and Scp Interventional Radiology LLC.
In the past Tom Bailey occupied the position of President at Angiotech Pharmaceuticals, Inc. and Chief Financial Officer at AgaMatrix, Inc.
Mr. Bailey received an undergraduate degree and an MBA from Harvard University. |
| Kenneth Thomas Bailey |
Mr. Kenneth T. Bailey is a Chief Financial Officer at NanoString Technologies, Inc., an Operating Partner at Peloton Equity LLC, a President at Point Technologies, Inc., a President, Secretary, Treasurer & Director at Angiotech America, Inc., a President, Secretary, Treasurer & Director at Argon Medical Devices Biocoatings Corp., a President, Secretary, Treasurer & Director at B.G. Sulzle, Inc. and a President, Secretary, Treasurer & Director at Quill Medical, Inc. He is on the Board of Directors at IZI Medical Products LLC, Homestretch Foundation, Scp Interventional Radiology LLC, Waveform Diabetes, Angiotech America, Inc., Argon Medical Devices Biocoatings Corp., B.G. Sulzle, Inc. and Quill Medical, Inc. Mr. Bailey was previously employed as a Chief Financial Officer & Treasurer by AgaMatrix, Inc., a Chief Financial Officer by Agamatrix Holdings LLC, a Director-Health Care Investment by Credit Suisse First Boston Corp., a Director-Health Care Investment by Donaldson, Lufkin & Jenrette International, a President, Treasurer & Director by American Medical Instruments, Inc., a President, Secretary, Treasurer & Director by Angiotech Pharmaceuticals (US), Inc., a President, Secretary, Treasurer & Director by Manan Medical Products, Inc., and a President, Secretary, Treasurer & Director by Surgical Specialties Corp. He also served on the board at LifeCare Management Services LLC, OncoGenex Pharmaceuticals, Inc. and Angiotech Pharmaceuticals, Inc. He received his undergraduate degree from Harvard University and an MBA from Harvard Business School. |
| William D. Young |
William D. Young is a businessperson who has been at the helm of 7 different companies. Presently, he is Chairman for NanoString Technologies, Inc. and Senior Advisor at Blackstone, Inc., Senior Advisor at Blackstone Life Sciences Advisors LLC (a subsidiary of Blackstone, Inc.). William D. Young is also Member of National Academy of Engineering and on the board of 5 other companies.
In his past career Mr. Young was Chairman of Biogen, Inc. and Chairman of Biogen Idec New Ventures, Inc. (a subsidiary of Biogen, Inc.), Chairman at AGY Therapeutics, Inc., Chairman for Annexon, Inc., Chairman & Chief Executive Officer for Monogram Biosciences, Inc., Chairman of TYRX, Inc., Chief Operating Officer of Genentech, Inc. and Venture Partner at Clarus Ventures LLC.
He received an MBA from Indiana University and an undergraduate degree from Purdue University. |
| Robert Bradley Gray |
Presently, Robert Bradley Gray holds the position of President, Chief Executive Officer & Director at NanoString Technologies, Inc.
In the past he was Director-Corporate Development at Genzyme Corp. and Vice President-Product & Business Development at Genzyme Genetics, Inc.
He received an undergraduate degree from the University of Oxford and an undergraduate degree from Massachusetts Institute of Technology. |
| Janet George |
Janet George is on the board of The Institute of Electrical & Electronics Engineers, Inc. and NanoString Technologies, Inc. She previously occupied the position of VP-Autonomous Enterprise & Advanced Analytics at Oracle Corp., Chief Data Scientist at Western Digital Corp., Senior Director-Advanced Machine Learning at Yahoo! Research Labs and Vice President-Sales & Marketing at Andale, Inc.
Ms. George received a graduate degree from the University of Kerala and an undergraduate degree from the University of Pune. |
| Kirk D. Malloy |
Kirk D. Malloy founded Bioadvisors LLC and Verogen, Inc. Currently, Dr. Malloy holds the position of Independent Chairman at Rapid Micro Biosystems, Inc. and Technical Advisory Board Member at Arboretum Ventures LLC. He is also Principal at Bioadvisors LLC and Associate for Growthsource, Inc. and on the board of 8 other companies.
In his past career he held the position of Lead Independent Director at Organovo Holdings, Inc., Chairman for Agilome, Inc., Senior Vice President & GM-Life Sciences at Illumina, Inc., Executive Chairman at Verogen, Inc., Director-Technical Services & Implementation at Alere San Diego, Inc. and Manager-Customer Operations at Qiagen, Inc.
Kirk D. Malloy received an undergraduate degree from the University of Miami and a graduate degree and a doctorate from the University of Delaware. |
| Dana E. Rollison |
Dana E. Rollison is on the board of NanoString Technologies, Inc. and Chief Data Officer & Vice President at H. Lee Moffitt Cancer Center & Research Institute, Inc.
Dr. Rollison received an undergraduate degree from the University of Miami and a doctorate and a graduate degree from The Johns Hopkins University. |
| Chad P. Waite |
Chad P. Waite occupies the position of Co-Managing Director at Twinstrand Biosciences, Inc., General Partner for OVP Venture Partners, General Partner for Olympic Venture Partners III LP, General Partner for Olympic Venture Partners IV LP, General Partner of OVP Venture Partners VII LP, Vice President & General Partner at Olympic Venture Partners II LP, General Partner of Olympic Venture Partners V LP and General Partner for OVP Venture Partners VI LP (which are all subsidiaries of OVP Venture Partners) and Investment Committee Member at W Fund Management LLC. Mr. Waite is also on the board of Kenyon College, NanoString Technologies, Inc., Acylin Therapeutics, Inc. and Cyrus Biotechnology, Inc. and General Partner of Olympic Venture Partners III LP, General Partner at Olympic Venture Partners IV LP, General Partner for OVP Venture Partners VII LP, Member of Oregon Health & Science University, Vice President & General Partner at Olympic Venture Partners II LP, General Partner at Olympic Venture Partners V LP, General Partner for OVP Venture Partners VI LP, Vice President of Northwest Venture Services Corp. and General Partner for Ovp Venture Partners II.
In his past career he held the position of Director at Accelerator Services Corp, Investment Committee Member at W Fund Management LLC, Principal at COBE Laboratories, Inc. and General Partner of Hambrecht & Quist LLC.
He received an undergraduate degree from Kenyon College and an MBA from Harvard University. |
| Teresa M. Foy |
Teresa M. Foy is on the board of NanoString Technologies, Inc. and Senior VP-Immuno Oncology & Cell Therapy at Bristol Myers Squibb Co.
In the past Dr. Foy occupied the position of Chief Scientific Officer at Oncofactor Corp., Chief Scientific Officer of Viral Logic Systems Technology Corp., Director-Preclinical Biology at Corixa Corp. and Director-Preclinical Development at GlaxoSmithKline Biologicals SA.
Teresa M. Foy received an undergraduate degree from the University of Minnesota, a doctorate from the University of Iowa and a graduate degree from St. Cloud State University. |
| Gregory Norden |
Currently, Gregory Norden occupies the position of Managing Director at G9 Capital Group LLC. He is also on the board of 6 other companies.
He previously occupied the position of Chief Financial Officer & Senior Vice President of Wyeth Corp., Chief Financial Officer & Executive Vice President for Wyeth Pharmaceuticals LLC, Vice President-Finance at Ayerst Laboratories, Inc. and Audit Manager at Arthur Andersen LLP.
He received a graduate degree from Long Island University and an undergraduate degree from State University of New York College at Plattsburgh. |
| Elisha Wade Finney |
Elisha Wade Finney is on the board of ICU Medical, Inc. and 4 other companies.
In her past career Ms. Finney occupied the position of Chief Financial Officer & Executive VP-Finance at Varian Medical Systems, Inc., Principal at The Fox Group, Inc. and Principal at Parmalat Dairy & Bakery, Inc.
Ms. Finney received an undergraduate degree from the University of Georgia and an MBA from Golden Gate University. |
